PA
DAVA icon

PharVision Advisers’s Endava DAVA Stock Holding History

PharVision Advisers’s Portfolio DAVA Stock Details DAVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,381
Closed -$116K – 245
2025
Q4 		$116K Buy
+18,381
New +$141K 0.06% 642

Other funds holding DAVA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
PIM
Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return
CU
CDAM (UK) London, United Kingdom $387M AUM 4.05% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1.16B AUM 53.61% 1-Year Est. Return
AIMCA
Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.56% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
KA
Kerrisdale Advisers Miami, Florida $399M AUM 42.87% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

PharVision Advisers's DAVA Position: Q1 2026 in Review

PharVision Advisers sold out of Endava (DAVA) in Q1 2026, closing a stake of 18,381 shares — an estimated $116K sold.

PharVision Advisers first reported a position in DAVA in Q4 2025 and held it in 1 quarter. The position peaked at $116K in Q4 2025. 80 funds tracked by Wall St. Rank hold DAVA as of Q1 2026.

  • PharVision Advisers reported no remaining Endava position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 18,381 Endava shares in Q1 2026, an estimated $116K.
  • PharVision Advisers first reported a position in Endava in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Endava position peaked at $116K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Endava as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.